Investor Presentation

July 19, 2026 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Limited First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No. C/1, ‘G’ Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai 400001 Bandra East Mumbai 400051 Fax No.2272 3121/2037/2039 Fax No.2659 8237/8238 Stock Code: 543213 Stock Code: ROSSARI Dear Sir/Madam, Subject: Q1 FY27 Earnings Presentation Please find enclosed a copy of the Earnings Presentation for the Quarter ended June 30, 2026. The same may please be taken on record and suitably disseminated to all concerned. Thanking you, Yours Sincerely, For Rossari Biotech Limited Parul Gupta Company Secretary & Head - Legal Membership No.: A38895 Encl.: as above ROSSARI BIOTECH LIMITED Q1 FY27 RESULTS PRESENTATION July 18, 2026 Disclaimer Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Ltd (Rossari) in the presentation (“forward-looking statements”) reflect various assumptions concerning the strategies, objectives and anticipated results which may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the presentation is provided to the recipient and Rossari is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this presentation or that this presentation is suitable for the recipient’s purposes. The delivery of this presentation does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof. 1 Q1 FY27 Results Overview 2 Company Overview 3 Annexure Q1 FY27 – Key Financial Highlights Record Quarterly Revenue and EBITDA Revenue from Operations (Rs. cr) EBITDA(Rs. cr) PAT(Rs. cr) 46.0 697.2 684.9 80.6 77.3 543.7 67.9 35.1 33.6 Q1 FY27 Q4 FY26 Q1 FY26 Q1 FY27 Q4 FY26 Q1 FY26 Q1 FY27 Q4 FY26 Q1 FY26 Shift % (Y-o-Y) 28.2% 18.7% 4.5% Shift % (Q-o-Q) 1.8% 4.3% -23.7% Margins (%) 11.6% 11.3% 12.5% 5.0% 6.7% 6.2% Business Sector contribution Q1 FY27 HPPC TSC AHN 79% 15% 6% Note: All figures, unless mentioned otherwise, are on a consolidated basis. Institutional and B2C Performance – Incubating Future Growth Verticals in Health & Hygiene Revenue (Rs. cr) EBITDA (Rs. cr) Q1 FY27 Q4 FY26 Q1 FY26 71 70 70 Q1 FY27 Q4 FY26 Q1 FY26 Shift % (Y-o-Y) 1% 43% Shift % (Q-o-Q) 1% -100% Margins (%) -6% -3% -10% • Performance in the Institutional and B2C segments remained flat in Q1 FY27 • Continued focus on portfolio rationalisation and improving the quality of revenues across these segments Consolidated Performance excluding Institutional and B2C Businesses Revenue (Rs. cr) EBITDA (Rs. cr) 626 615 75 Q1 FY27 Q4 FY26 Q1 FY26 Q1 FY27 Q4 FY26 Q1 FY26 Shift % (Y-o-Y) 32% 13% Shift % (Q-o-Q) 2% 8% Margins (%) 14% 13% 16% • Core segments delivered strong growth, supported by a diversified portfolio and strong customer engagement across markets • Performance across HPPC, TSC and AHN remained broad-based, supported by balanced end-market exposure and continued progress in exports and new business development • Excluding Institutional and B2C businesses, EBITDA margin in Q1 FY27 stood at 14%, reflecting the underlying strength and stability of the core B2B business Past Financial Performance Snapshot Revenue (Rs. cr) EBITDA (Rs. cr) PAT (Rs. cr) CAGR – 13% CAGR – 9% CAGR – 12% 286 131 136 2,396 250 265 2,080 223 107 1,831 1,656 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Exports (Rs. cr) ROE (%) ROCE (%) Net Debt to Equity (x) CAGR – 19% 21.0 21.0 570 17.0 0.21 15.0 448 0.04 0.06 13.0 12.0 12.0 12.0 -0.08 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 • Consistent growth trajectory over the past four years, driven by both organic and inorganic growth strategies • While near-term investments and strategic initiatives have led to a moderation in ROCE and ROE, the balance sheet position remains strong. The Company is confident of reporting improved return metrics in the future as these investments start yielding results Management Message Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We commenced FY27 on a strong note, delivering robust consolidated revenue growth of 28% YoY. The performance was driven by healthy momentum in the domestic business and the continued expansion of our international presence. Despite a dynamic operating environment, our diversified business model, broad-based market presence and disciplined execution enabled us to deliver growth across all our business segments. Our HPPC, TSC and AHN businesses delivered YoY growth of 28%, 28% and 27%, respectively, reflecting healthy momentum across the portfolio. Performance was supported by deeper market penetration, expansion into new applications and a higher contribution from differentiated, value-added specialty solutions across end-user industries. Our international business continued to make steady progress, supported by higher wallet share with global partners and growing acceptance of our specialty solutions across key overseas markets. During the quarter, we further strengthened our regional presence with the establishment of a greenfield blending facility in Thailand, designed to serve Southeast Asia. The facility will enhance our ability to offer customised formulations, respond swiftly to local market requirements and improve supply-chain efficiency. Over the past few years, we have made focused investments in developing new capabilities, innovation and product development. Capacity utilisation across these investments has been improving steadily, and our priority is now to drive optimal utilisation, strengthen the product portfolio and enhance operational efficiencies. Together with our robust R&D platform, these efforts will enable us to address evolving industry requirements and reinforce our competitive positioning. As we progress through FY27, we remain focused on disciplined execution, innovation and profitable growth. Supported by a healthy balance sheet, an integrated manufacturing platform and an expanding global presence, we are well-positioned to capitalise on emerging opportunities and create sustainable long-term value for all our stakeholders.” Key Developments • Strengthened Southeast Asia Presence through Thailand Facility o Established a greenfield blending facility in Thailand through the Company’s subsidiary, Unistar Thai o Installed capacity of 5,000 MTPA, with capabilities across powders, granules and liquids o Designed to offer customised formulations aligned with local market requirements • Progress on Monetisation of Non-Core Assets o Completed the sale of the Company’s Andheri office during the quarter o Marks further progress in the Company's ongoing monetisation of non-core assets, following the sale of the Kanjurmarg office in the previous quarter. Abridged P&L Statement - Consolidated Particulars (Rs. cr) Q1 FY27 Q1 FY26 Y-o-Y FY26 FY25 Y-o-Y Revenues from Operations 697.2 543.7 28.2% 2,396.4 2,080.3 15.2% Total Expenditure COGS 490.8 371.3 32.2% 1,668.7 1,433.3 16.4% Employee benefits expense 44.1 37.5 17.6% 154.7 132.3 16.9% Other expenses 81.7 67.0 21.9% 287.0 249.6 15.0% EBITDA 80.6 67.9 18.7% 286.0 265.1 7.9% EBITDA Margin (% [Showing first 8,000 characters — download PDF for full document]